Dear Shareholders and readers
Diamyd Medical is spearheading an important change in the treatment of autoimmune diabetes - we develop a new class of tailored therapies that intervene early in the disease progression. The change is important and urgent. Although new assistive technologies are increasingly being adopted by patients, there has so far been limited real world impact on patient outcomes. At the same time, there is an unsustainable increase in the pricing of chronic maintenance treatments,...